Treatment response in pediatric metabolic dysfunction-associated steatotic liver disease: Noninvasive endpoints and body composition

doi:10.4254/wjh.125487

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 10

This Article

(4)

(3)

(0)

(30)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Oct 27, 2026; 18(10): 125487
Published online Oct 27, 2026. doi: 10.4254/wjh.125487

Treatment response in pediatric metabolic dysfunction-associated steatotic liver disease: Noninvasive endpoints and body composition

Toshifumi Yodoshi

Toshifumi Yodoshi, Division of Gastroenterology, Hepatology, Pancreatology and Nutrition, University of Iowa Stead Family Children’s Hospital, Iowa City, IA 52242, United States

Author contributions: Yodoshi T conceptualized and designed the review, conducted the literature search, analyzed and interpreted the literature, and drafted and critically revised the manuscript; the author read and approved the final version.

AI contribution statement: AI was not used to generate or analyze study data.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Corresponding author: Toshifumi Yodoshi, MD, PhD, Clinical Assistant Professor, Division of Gastroenterology, Hepatology, Pancreatology and Nutrition, Stead Family Children’s Hospital, 200 Hawkins Drive, Iowa City, IA 52242, United States. toshifumi-yodoshi@uiowa.edu

Received: July 8, 2026
Revised: August 9, 2026
Accepted: September 18, 2026
Published online: October 27, 2026
Processing time: 105 Days and 10.2 Hours

Core Tip

Core Tip: Treatment response in pediatric metabolic dysfunction-associated steatotic liver disease cannot currently be defined by a single biomarker. Alanine aminotransferase, liver fat, liver stiffness, histology, cardiometabolic health, growth, body composition, and patient-reported outcomes capture complementary domains and may change at different rates. Diagnostic or prognostic performance does not by itself establish longitudinal responsiveness. This review separates those measurement properties, qualifies adult-derived thresholds, and proposes a three-tier, treatment-aware framework that distinguishes hepatic improvement with preserved muscle and normal growth from weight loss alone.